

UNITED STATES Â SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K Â REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 Â For the month ofÂ February 2025 Â Commission File Number:Â 001-36187 EVOGENE LTD. Â Â (Translation of Registrantâ€™s Name into English) Â 13 Gad Feinstein Street, Park Rehovot, Rehovot 7638517, Israel (Address of principal executive offices) Â Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Â Form 20-FÂ ~Â Â Â Â Â Form 40-F ~ CONTENTS Â On February 5, 2025, Evogene Ltd. (the â€œCompanyâ€) convened its Special General Meeting of Shareholders (the â€œAnnual Meetingâ€), however, it was adjourned for one week to the same day, time and place due to lack of quorum. Accordingly, the Companyâ€™s Special General Meeting will be reconvened on Wednesday, February 12, 2025 at 3:00Â p.m. (Israel time), at the executive offices of the Company, 13Â Gad Feinstein Street, Park Rehovot, Rehovot, Israel. Â The content of this Report of Foreign Private Issuer on Form 6-K is incorporated by reference into the registration statements on Form F-3 (File No. 333-277565) and on Form S-8 (SEC File Nos.Â 333-193788,Â 333-201443,Â 333-203856Â andÂ 333-259215) of the Company, and will be a part thereof from the date on which this Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. Â Â Signature Â Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Â Date: February 5, 2025 EVOGENE LTD. (Registrant) By:Â /s/ Yaron Eldad Yaron Eldad Chief Financial Officer